Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2013

View Archived Issues

Researchers present preclinical results for ML-297

Characterization and development of a potent inhibitor of cholesterol biosynthesis

Novel podophyllotoxin derivatives with significant antitumor activity presented

ACT-001 demonstrates efficacy and high oral bioavailability in vivo

Trial of gene therapy for Sanfilippo B syndrome begins

Suven presents a novel 5-HT6 receptor antagonist for the treatment of AD

New alpha-type CGRP receptor antagonists disclosed by Merck & Co.

Canadian group designs novel heteromultimer constructs for cancer

Healios and DSP sign Japanese joint development agreement for iPS-derived RPE cells

Vital Therapies enrolls first subject in Australia in phase III VTI-208 trial

FDA extends PDUFA date for Alprolix BLA

First patient treated in phase I/II HGB-205 study

FDA accepts Zalviso NDA for filing

Isis Pharmaceuticals earns milestone payment from GSK for ISIS-TTRRx

Actelion provides update on the DUAL program

NeurOp divulges novel NMDA receptor antagonists

Immunotherapeutic 3M-052 shows oncolytic potential

EMD Serono launches TocopheRx, a new spin-off focused on infertility treatment

Novel immunogenic peptide compositions presented by French group

ProJect Pharmaceutics signs agreement to develop new formulation of IMX-101

Novel CDK inhibitor unaffected by transporter-dependent drug resistance

Phase II all-oral combination study of simeprevir, TMC-647055 and samatasvir begins

PharmAthene terminates merger agreement with Theraclone Sciences

Baxter submits amended BLA for HyQvia

Forest Laboratories to acquire U.S. rights to Saphris

FDA grants orphan drug designation to Conatus' emricasan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...